Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Rhea-AI Summary

Entera Bio (Nasdaq: ENTX) closed a $10.0 million private placement on April 2, 2026, led by funds affiliated with BVF Partners L.P.

Entera sold 7,827,789 units at $1.2775 per unit; each unit includes one ordinary share (or a pre-funded warrant) and a five-year warrant to buy 1.5 shares at $1.24.

Gross proceeds were approximately $10 million, with potential additional cash of ~ $14.5 million if all warrants are exercised, for total potential proceeds of ~ $24.5 million. Net proceeds will support the planned Phase 3 registrational study of EB613 and general corporate purposes.

Positive

• $10.0M gross proceeds from the April 2, 2026 private placement
• Potential $24.5M total proceeds if all warrants are exercised for cash (~$14.5M additional)
• Financing led by BVF Partners, indicating institutional investor support

Negative

• Issuance of 7,827,789 units creates immediate share/warrant dilution risk
• Warrants exercisable for 1.5 shares at $1.24 could materially increase share count if fully exercised

News Market Reaction – ENTX

-5.56%

2 alerts

-5.56% Session close to close

-8.5% Trough Tracked

$55.01M Market Cap

0.4x Rel. Volume

In the Apr 6 session, ENTX declined 5.56%, reflecting a notable negative market reaction. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.6% in the session following this news. A negative reaction despite the financing ...

Analysis

The stock moved -5.6% in the session following this news. A negative reaction despite the financing would have fit past instances where fundamental updates led to weaker trading, such as earnings and clinical protocol news that preceded price declines of up to double digits. Even with potential proceeds of $24.5 million, the market could have focused on dilution from 7,827,789 new units and attached warrants. In that case, sentiment around capital needs versus ownership dilution might have weighed more than the support for the EB613 Phase 3 program.

Key Figures

Private placement size: $10 million Units issued: 7,827,789 units Unit purchase price: $1.2775 per unit +5 more

8 metrics

Private placement size $10 million Gross proceeds from BVF-led private placement

Units issued 7,827,789 units Aggregate units sold in the private placement

Unit purchase price $1.2775 per unit Pricing of units in private placement

Warrant exercise price $1.24 per share Exercise price for five-year ordinary share warrants

Warrant premium 11.7% premium Premium to recent closing market price for warrant exercise

Potential additional proceeds $14.5 million If all warrants issued are exercised for cash

Total potential proceeds $24.5 million Gross plus potential warrant proceeds from financing

Warrant term 5 years Duration of ordinary share warrants in each unit

Historical Context

5 past events · Latest: Apr 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 02	Private placement	Positive	+10.5%	BVF-led $10M unit financing with warrants and Phase 3 funding focus.
Mar 27	Earnings update	Neutral	-11.5%	2025 results, cash runway to mid‑Q3 2026, EB613 and pipeline updates.
Mar 04	Clinical protocol	Positive	-3.0%	Submission of streamlined Phase 3 protocol for EB613 to FDA.
Feb 26	Conference appearance	Neutral	-4.4%	Announcement of CEO participation in Leerink healthcare conference.
Feb 11	Insider buying	Positive	+13.1%	Board members disclosed open-market purchases of company shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often triggered sizable moves, with positive financings and insider buying aligning with gains, while earnings and clinical updates saw negative or muted reactions.

Recent Company History

Over the past two months, Entera Bio has reported multiple catalysts, including insider share purchases in February 2026, conference participation, a streamlined Phase 3 protocol submission for EB613 on Mar 4, 2026, full-year 2025 results with cash runway into mid‑Q3 2026, and the BVF-led private placement announced on Apr 2, 2026. The current law-firm announcement reflects the same financing, supporting the planned Phase 3 registrational study of EB613 in postmenopausal osteoporosis.

Key Terms

private placement, pre-funded warrant, warrant, exercise price, +2 more

6 terms

private placement financial

"advised Israel-based Entera Bio Ltd. ... in a $10 million private placement led by funds"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrant financial

"Each unit consists of one ordinary share of Entera, or a pre-funded warrant in lieu thereof"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

warrant financial

"and a five-year warrant to purchase one and a half ordinary shares at an exercise price"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

exercise price financial

"one and a half ordinary shares at an exercise price of $1.24 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Phase 3 registrational study medical

"to support activities related to the initiation of its Phase 3 registrational study of EB613"

A phase 3 registrational study is a large, late-stage clinical trial designed to show whether a drug or medical treatment is effective and safe enough for regulators to approve it for market use. Investors care because the study’s results are often the decisive evidence that determines whether a product can be sold, which directly affects a company’s future revenue, valuation and risk—think of it as the final exam or road test before a product can enter widespread use.

postmenopausal women with osteoporosis medical

"Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis"

Women who have gone through menopause and have reduced bone density that increases their risk of fractures; think of their skeleton like an aging scaffold that becomes thinner and more brittle. This group matters to investors because it represents a defined patient population for drugs, medical devices and diagnostics, shapes clinical trial design and regulatory approval criteria, and influences market size, pricing and reimbursement decisions in the bone-health sector.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the development of oral peptide and protein replacement therapies, in a $10 million private placement led by funds affiliated with private investment firm BVF Partners L.P.

Under the terms of the transaction, which closed April 2, Entera issued and sold an aggregate of 7,827,789 units at a purchase price of $1.2775 per unit, according to the company's press release. Each unit consists of one ordinary share of Entera, or a pre-funded warrant in lieu thereof, and a five-year warrant to purchase one and a half ordinary shares at an exercise price of $1.24 per share, representing an 11.7% premium to the company's recent closing market price.

Gross proceeds from the private placement were approximately $10 million, before deducting offering expenses. If all warrants issued in the financing are exercised for cash, Entera could receive additional proceeds of approximately $14.5 million, resulting in total potential proceeds of approximately $24.5 million.

The Greenberg Traurig team advising Entera was led by Drew M. Altman, co-chair of the Miami Corporate Practice, with Corporate Shareholder Sami B. Ghneim and Law Clerk Elizabeth Ferrie supporting.

Entera disclosed that it intends to use the net proceeds from the private placement, together with its existing cash and cash equivalents, to support activities related to the initiation of its Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis, as well as for working capital and general corporate purposes.

About Greenberg Traurig: Greenberg Traurig, LLP has more than 3,100 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenberg-traurig-represents-israel-based-entera-bio-in-10m-private-placement-led-by-bvf-partners-302734765.html

SOURCE Greenberg Traurig, LLP

FAQ

What did Entera Bio (ENTX) raise in the April 2, 2026 private placement?

Entera raised approximately $10.0 million in gross proceeds from the private placement. According to the company, 7,827,789 units were sold at $1.2775 per unit, with five-year warrants attached that could raise additional proceeds if exercised.

How much additional cash could Entera Bio (ENTX) receive if all warrants are exercised?

If all warrants are exercised for cash, Entera could receive about $14.5 million more. According to the company, that would result in total potential proceeds of approximately $24.5 million including the initial $10.0 million.

What are the terms of the warrants issued in Entera Bio's (ENTX) financing?

Each unit included a five-year warrant to buy 1.5 ordinary shares at an exercise price of $1.24 per share. According to the company, the exercise price represented an 11.7% premium to recent closing market price.

How will Entera Bio (ENTX) use the proceeds from the $10M private placement?

Entera intends to use net proceeds to support initiation of its Phase 3 registrational study of EB613, plus working capital and general corporate purposes. According to the company, existing cash will be combined with the financing proceeds.

Who led the $10M private placement for Entera Bio (ENTX) and when did it close?

The financing was led by funds affiliated with BVF Partners L.P. and closed on April 2, 2026. According to the company, Greenberg Traurig advised Entera on the transaction.